^
    Back
    Association details:
    Biomarker:KDM5C mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancers (Basel)
    Title:

    Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

    Published date:
    06/06/2022
    Excerpt:
    Analysis of seven ICB-treated NSCLC cohorts revealed that mutations of three chromatin remodeling-related genes, including KMT2C, BCOR and KDM5C, were significantly associated with ICB response, and combined mutations of these three genes further enhance this association. NSCLC patients with KMT2C/BCOR/KDM5C mutations had comparable clinical outcomes to TMB-high patients in terms of objective response rate, durable clinical benefit and overall survival.
    DOI:
    https://doi.org/10.3390/cancers14112816
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2020
    Title:

    P75.08 - KDM5C Mutation Is Associated with Better Immunotherapy Outcomes in Non–Small Cell Lung Cancer

    Published date:
    01/12/2021
    Excerpt:
    NSCLC...patients received immunotherapy...median progression-free survival was 13.2 months (95% CI, 4.4 to 22.0) in the KDM5C mutations group...KDM5C mutations are associated to better efficacy of immunotherapy…